Predicted Top 5 Worldwide Selling Drugs in 2025: A Market Update
Keytruda ($30B sales), Ozempic, Mounjaro, Dupixent, and Skyrizi dominate 2025's pharma market, targeting oncology, diabetes/obesity, and immunology with breakthrough biologics and multi-indication strategies.
June 23, 2025
by David Orchard-Webb
Lilly’s tirzepatide beats Ozempic in head-to-head type 2 diabetes trial
Eli Lilly has announced that its investigational GIP and GLP-1 inhibitor tirzepatide showed superiority over Novo Nordisk’s Ozempic in a Phase III trial.
June 29, 2021
by pharmatimes
Investigational 2 mg Dose of Ozempic (semaglutide) Injection Demonstrates Superior Reductions in Blood Sugar vs Ozempic 1 mg in Adults With Type 2 Diabetes in a Phase 3 Trial
Novo Nordisk today presented data showing that an investigational 2 mg dose of Ozempic® (semaglutide) injection provided statistically significant and superior reductions in blood sugar (A1C) compared with Ozempic®1 mg.
June 28, 2021
by firstwordpharma
Good News in the Chinese Diabetes Field and Several Original Research Drugs Underway
Glad tidings came recently in terms of supervision of two domestic diabetes drugs. Semaglutide, Novo Nordisk's blockbuster hypoglycemic drug, advanced to the administrative approval stage (acceptance number: JXSS2000005/6) on April 20.
May 25, 2021
by PharmaSources/Dopine
FDA Approves New Indication for Ozempic, Updated Rybelsus Prescribing Information
Novo Nordisk announced the U.S. Food and Drug Administration (FDA) has approved a new indication for Ozempic® (semaglutide) injection 0.5 mg or 1 mg to reduce the risk of major adverse cardiovascular events (MACE) such as heart attack, stroke ...
January 19, 2020
by americanpharmaceuticalreview
Novo Nordisk secures FDA expanded indication for Ozempic
The US Food and Drug Administration (FDA) has approved a new indication for Novo Nordisk’s Ozempic (semaglutide). The once-weekly injection is now indicated to reduce the risk of major adverse cardiovascular events (MACE) ...
January 19, 2020
by pharmaceutical-technology
Novo's Ozempic launch kicks into gear ahead of oral semaglutide FDA decision
Novo Nordisk has suffered some well-documented insulin woes, but now the company has not just two, but three GLP-1 drugs stepping up to drive growth. And if all goes well at the FDA, another big approval is on tap this year.
August 11, 2019
by fiercepharma
Novo Nordisk files for EU approval of Ozempic in type II diabetes
Novo Nordisk has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Ozempic (oral semaglutide), for the treatment of type II diabetes.
April 28, 2019
by pharmatimes
Ozempic consistently reduced the risk of major cardiovascular events across type 2 diabetes populations at high CV risk regardless of prior CV events at baseline
Munich, Germany, 26 August 2018 - Ozempic® (semaglutide) consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack......
August 27, 2018
by firstwordpharma
Novo Nordisk channels '70s 'Magic' in first TV ad for blockbuster-in-waiting Ozempic
Novo Nordisk debuted its first DTC campaign for Type 2 diabetes drug Ozempic this week, setting the promotional stage for its aspiring blockbuster.
August 2, 2018
by fiercepharma
Novo Nordisk results show GLP-1s are job 1. Can its crucial Ozempic launch deliver?
After Eli Lilly reported street-beating diabetes sales in the first quarter while Sanofi’s suffered, all eyes were turned to Novo Nordisk.
May 3, 2018
by fiercepharma
Novo bags first approval for once-weekly diabetes drug
Novo Nordisk has garnered its first global approval for its once-weekly diabetes therapy Ozempic in the US.
December 7, 2017
by pharmatimes